122 related articles for article (PubMed ID: 33725911)
1. p-STAT3 expression in breast cancer correlates negatively with tumor size and HER2 status.
Wang Y; Wang Q; Tang CH; Chen HD; Hu GN; Shao JK; Dong XF; Jin LL; Wang CQ
Medicine (Baltimore); 2021 Mar; 100(10):e25124. PubMed ID: 33725911
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
3. Molecular subtype can predict the response and outcome of Chinese locally advanced breast cancer patients treated with preoperative therapy.
Chen XS; Wu JY; Huang O; Chen CM; Wu J; Lu JS; Shao ZM; Shen ZZ; Shen KW
Oncol Rep; 2010 May; 23(5):1213-20. PubMed ID: 20372832
[TBL] [Abstract][Full Text] [Related]
4. [Clinicopathological characteristics and prognosis of different molecular types of breast cancer].
Liu ZF; Chen C; Yao XL; Sun SR
Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(22):1733-7. PubMed ID: 27356638
[TBL] [Abstract][Full Text] [Related]
5. Biological Characteristics and Long-term Outcomes in Node-negative Breast Cancer.
Agostinetto E; Giordano L; Torrisi R; De Sanctis R; Masci G; Losurdo A; Zuradelli M; Tinterri C; Gatzemeier W; Testori A; Alloisio M; De Rose F; Fernandes B; Santoro A
Clin Breast Cancer; 2020 Aug; 20(4):e481-e489. PubMed ID: 32279915
[TBL] [Abstract][Full Text] [Related]
6. Tissue microarray-based study of patients with lymph node-positive breast cancer shows tyrosine phosphorylation of signal transducer and activator of transcription 3 (tyrosine705-STAT3) is a marker of good prognosis.
Sonnenblick A; Shriki A; Galun E; Axelrod JH; Daum H; Rottenberg Y; Hamburger T; Mali B; Peretz T
Clin Transl Oncol; 2012 Mar; 14(3):232-6. PubMed ID: 22374428
[TBL] [Abstract][Full Text] [Related]
7. p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial.
Sonnenblick A; Salgado R; Brohée S; Zahavi T; Peretz T; Van den Eynden G; Rouas G; Salmon A; Francis PA; Di Leo A; Crown JPA; Viale G; Daly L; Javdan B; Fujisawa S; De Azambuja E; Lieveke A; Piccart MJ; Bromberg JF; Sotiriou C
Int J Oncol; 2018 Feb; 52(2):424-432. PubMed ID: 29207087
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and predictive value of the combination of TOP2A and HER2 in node-negative tumors 2 cm or smaller (T1N0) breast cancer.
Zhong W; Yang Y; Zhang A; Lin W; Liang G; Ling Y; Zhong J; Yong J; Liu Z; Tian Z; Lin Q; Luo Q; Li Y; Gong C
Breast Cancer; 2020 Nov; 27(6):1147-1157. PubMed ID: 32780321
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort.
Johansson ALV; Trewin CB; Hjerkind KV; Ellingjord-Dale M; Johannesen TB; Ursin G
Int J Cancer; 2019 Mar; 144(6):1251-1261. PubMed ID: 30367449
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
Prat A; Cheang MC; Galván P; Nuciforo P; Paré L; Adamo B; Muñoz M; Viladot M; Press MF; Gagnon R; Ellis C; Johnston S
JAMA Oncol; 2016 Oct; 2(10):1287-1294. PubMed ID: 27281556
[TBL] [Abstract][Full Text] [Related]
11. Human epidermal growth factor receptor 2 expressions and Janus-activated kinase/signal transducer and activator of transcription 3-suppressor of cytokine signaling 3 pathway may be associated with clinicopathological features and prognosis of gastric cancer.
Xu W; Fu J; Wu H; Sun W
J Cancer Res Ther; 2018 Jun; 14(Supplement):S311-S318. PubMed ID: 29970682
[TBL] [Abstract][Full Text] [Related]
12. HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients.
Bae SY; La Choi Y; Kim S; Kim M; Kim J; Jung SP; Choi MY; Lee SK; Kil WH; Lee JE; Nam SJ
Breast Cancer Res Treat; 2013 Jun; 139(3):741-50. PubMed ID: 23722313
[TBL] [Abstract][Full Text] [Related]
13. Interaction between STAT3 and GLI1/tGLI1 oncogenic transcription factors promotes the aggressiveness of triple-negative breast cancers and HER2-enriched breast cancer.
Sirkisoon SR; Carpenter RL; Rimkus T; Anderson A; Harrison A; Lange AM; Jin G; Watabe K; Lo HW
Oncogene; 2018 May; 37(19):2502-2514. PubMed ID: 29449694
[TBL] [Abstract][Full Text] [Related]
14. Expression of YES-associated protein (YAP) and its clinical significance in breast cancer tissues.
Cao L; Sun PL; Yao M; Jia M; Gao H
Hum Pathol; 2017 Oct; 68():166-174. PubMed ID: 28899737
[TBL] [Abstract][Full Text] [Related]
15. Effect of adjuvant chemotherapy in patients with ER + /HER2- breast cancer, assessed by propensity score matching: significance of nuclear grade and nodal status.
Tanaka N; Hirano A; Hattori A; Ogura K; Kamimura M; Inoue H; Yukawa H; Sakaguchi S; Matsuoka A; Kodera A; Shimizu T
Breast Cancer; 2021 Jan; 28(1):40-47. PubMed ID: 32592141
[TBL] [Abstract][Full Text] [Related]
16. Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients.
Cantini L; Pistelli M; Merloni F; Fontana A; Bertolini I; De Angelis C; Bastianelli L; Della Mora A; Santinelli A; Savini A; Maccaroni E; Diodati L; Falcone A; Berardi R
Clin Breast Cancer; 2020 Feb; 20(1):e89-e98. PubMed ID: 31378534
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-124 enhances response to radiotherapy in human epidermal growth factor receptor 2-positive breast cancer cells by targeting signal transducer and activator of transcription 3.
Fu Y; Xiong J
Croat Med J; 2016 Oct; 57(5):457-464. PubMed ID: 27815936
[TBL] [Abstract][Full Text] [Related]
18. Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study.
Su Y; Zheng Y; Zheng W; Gu K; Chen Z; Li G; Cai Q; Lu W; Shu XO
BMC Cancer; 2011 Jul; 11():292. PubMed ID: 21749714
[TBL] [Abstract][Full Text] [Related]
19. Population-Based Study on Cancer Subtypes, Guideline-Concordant Adjuvant Therapy, and Survival Among Women With Stage I-III Breast Cancer.
Hsieh MC; Zhang L; Wu XC; Davidson MB; Loch M; Chen VW
J Natl Compr Canc Netw; 2019 Jun; 17(6):676-686. PubMed ID: 31200362
[TBL] [Abstract][Full Text] [Related]
20. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
